tbuckley/cabot-search huggingface dataset:
SAT0076 Assessment of Quality in Clinical Management of Patients with Rheumatoid Arthritis. Are we Using the “Treat to Target” Strategy?
Authors: J.L. Andreu, M.A. Martín-Martínez, A. Gil, H. Corominas, J.J. Pérez-Venegas, J.A. Román-Ivorra, F. Sánchez-Alonso, T. Jimenez, M.A. Sanchez Ruiz
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The current paradigm of optimal clinical management of patients with rheumatoid arthritis (RA) recommends reaching a state of remission or low activity of the disease, assessed by composite indexes of activity, by means of a tight control and a dynamic adjustment of available therapeutic options, using a "treat to target" strategy. <h3>Objectives</h3> The aim of this work is to assess the level of implementation of the "treat to target" strategy and other parameters of medical quality in clinical records (CRs) of RA patients in Spanish rheumatology departments. <h3>Methods</h3> Adult RA patients fulfilling 2010 ACR-EULAR criteria for RA and diagnosed between January 1st, 2010 and December 31st, 2013 in Spanish rheumatology departments were included. From every centre, 19 patients were randomly chosen from a computerized anonymized list provided by every department. Independent auditors assessed the CRs, verifying the fulfilling of the quality criteria included in an assessment tool specifically developed for this project. The study was approved by the ethic committees of every participant hospital. Descriptive statistics were used for the presentation of the results. <h3>Results</h3> A total of 254 CRs from 14 rheumatology departments were included. An explicit assessment of the disease activity as a determinant element considered to choose the therapy was recorded in 32% of the CRs. An optimal escalation of methotrexate dose was registered in 77% of the cases. Use of a composite disease activity score (DAS28, SDAI, CDAI) was reported in 88% of the cases. Disease activity monitoring every 6-8 months after reaching the therapeutic target was recorded in 57% of the cases. In 96% of the cases, the clinicians had registered patient9s comorbidities and these associated conditions had been considered in planning the therapeutic approach and objective. In only 3.8% of the CRs, visits every 4 weeks using a composite activity score had been reported during the early stage while trying to reach remission after diagnosis. Starting a DMARD in the first two weeks after diagnosis was recorded in only 30% of the cases. <h3>Conclusions</h3> Currently, the implementation of the "treat to target" strategy is scarcely registered in clinical records of patients diagnosed with RA in Spanish rheumatology departments. <h3>Disclosure of Interest</h3> None declared
Efficient mRNA delivery with graphene oxide-polyethylenimine for generation of footprint-free human induced pluripotent stem cells
Authors: Hye Yeon Choi, Tae-Jin Lee, Gwang-Mo Yang, Jaesur Oh, Jihye Won, Jihae Han, Gun-Jae Jeong, Jongpil Kim, Jin-Hoi Kim, Byung-Soo Kim, Ssang-Goo Cho
Journal: Journal of Controlled Release (2016)
Mixed-Culture Cytopathogenicity Between KC and XC Oncornavirus Indicator Lines and “Virus-Free” Human Choriocarcinoma Cells 2
Authors: Kenneth H. Rand, Barbara Reed, Isadel Broseus, Berge Hampar, Raymond Gilden, Cedric Long
Journal: JNCI Journal of the National Cancer Institute (1976)

When rat (XC) cells transformed by Rous sarcoma virus and human (KC) cells were cocultivated with appropriate infected cells, cell fusion was extensive and rapid. Many human cell lines were screened, with negative results; however, several hormone-secreting human choriocarcinoma cells fused extensively with both KC and XC cells. No evidence of a virus involvement in this interaction was found by direct examination, transmission, or immunologic tests.
STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS
Authors: Chitra Venugopal, Robin Hallett, Parvez Vora, Branavan Manoranjan, Sujeivan Mahendram, Maleeha Qazi, Nicole McFarlane, Minomi Subapanditha, Sara Nolte, Mohini Singh, David Bakhshinyan, Neha Garg, Lach Boleslaw, Provias John, Kesava Reddy, Naresh Murty, Bradley Doble, Mickie Bhatia, John Hassell, Sheila Singh
Journal: Neuro-Oncology (2015)
Lasofoxifene in Postmenopausal Women with Osteoporosis
Authors: Lucía Silva-Fernández, José-Luis Andreu
Journal: New England Journal of Medicine (2011)

corrections not the subgroup of high-risk patients eligible for our study, among whom survival rates have historically been in the range of 25 to 35%. 3 We agree that the use of improved technology to assess prognostic biomarkers and response correlates may be helpful, and we included several such markers in this trial.A review of these data, acquired as secondary objectives, is ongoing and will be reported separately.Expedited reporting of the primary aim of this study (event-free survival) was, in our view, necessary, since the results would have an immediate influence on patient care.
Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study.
Authors: E. S. Saloustros, K. Kalbakis, N. K. Vardakis, A. Kalykaki, G. Milaki, M. Rovithi, S. Agelaki, Z. Saridaki, V. Georgoulias, D. Mavroudis
Journal: Journal of Clinical Oncology (2010)

1133 Background: Continuous administration of low dose oral vinorelbine, given three times a week (metronomic) is feasible and exceptionally well tolerated. Early results show activity against refractory tumors and provide evidence towards clinical proof of efficacy for metronomic chemotherapy. Recently, initial therapy of metastatic breast cancer (MBC) with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone. In this study vinorelbine metronomic and bevacizumab was evaluated as salvage therapy in women with MBC. Methods: Eligible patients with MBC had ≥1 prior chemotherapy regimens and ECOG PS ≤2. Patients received vinorelbine p.o. (50 mg 3 times a week) and iv bevacizumab 10 mg/kg every 14 days. Therapy was continued until disease progression or the appearance of unacceptable toxicity. The primary endpoint was objective response rate (ORR). We report the results of a preplanned analysis in 13 evaluable patients. Results: The median age of the patients was 67 (range 41–80) and were treated for a median of 5 cycles (range 1-9). The ORR was 7.7% with partial response (PR) in one patient and stable disease (SD) in 7 (53.8%) while the overall clinical benefit (PR+SD) was 53.6% and the TTP 4.5 months. Significant toxicities were uncommon, with grade 3 toxicities occurred in only one of the patients (neutropenia). As per protocol prespecified stopping rule, the study was closed early due to lack of efficacy. Conclusions: The combination of vinorelbine metronomic and bevacizumab shows good tolerance but minimal activity in terms of objective responses as salvage treatment of patients with MBC. No significant financial relationships to disclose.
Managed health care and the Massachusetts experience
Authors: L I Sederer, R L St Clair
Journal: American Journal of Psychiatry (1989)

Managed health care, through prepaid health delivery systems and utilization review organizations, is perhaps the greatest trend in modern health care. The authors examine the remarkable growth of managed care and outline its clinical, economic, ethical, and practical implications. They then review examples of how organized psychiatry has been involved in managed care and describe the efforts to date of the Massachusetts Psychiatric Society in this area. Managed care is here to stay. The future climate of psychiatric practice and the care available to psychiatric patients are dependent on informed and organized activities by psychiatrists and their local and national representatives.
MTR-07GLIOBLASTOMA ADAPTATION TO SUSTAINED cdk4/6 INHIBITION INVOLVES SUPPRESSION OF Rb EXPRESSION THROUGH HISTONE H3K4 MODIFICATION
Authors: Yu-Jen Lu, Yu-Jung Chang, Linyi Cheng, Kuo-Chen Wei, Tomoko Ozawa, Jung-Sik Kim, Todd Waldman, C. David James
Journal: Neuro-Oncology (2015)

We have previously shown that pharmacologic inhibition of cdk4/6, in preclinical, Rb proficient models of glioblastoma (GBM), slows tumor growth, and extends the survival of animal subjects with intracranial GBM xenografts. In the current study we examined molecular characteristics of two distinct GBM xenograft models that developed resistance to cdk4/6 targeted therapy when subjected to sustained inhibitor treatment. For each model, mice with intracranial GBM xenograft, established from G55 and U87 cells, received daily administration of inhibitor, which slowed tumor growth, as indicated by bioluminescence imaging, and significantly extended animal subject survival (p < 0.001). However, tumor bioluminescence slowly increased during the course of treatment, and all treatment group mice eventually succumbed to tumor burden. Intracranial tumor, from mice subjected to continuous daily inhibitor treatment, was dissected from mouse brain, then minced and injected subcutaneously into new athymic host mice, with host mice continuing to receive daily administration of cdk4/6 inhibitor until engrafted subcutaneous tumors showed growth rates comparable to corresponding subcutaneous tumors that were left untreated. Subcutaneous tumors exposed to continuous daily inhibitor treatment were used as cell sources for intracranial therapy response experiments, with results showing that tumors subjected to continuous and extended daily administration of inhibitor no longer responded to inhibitor treatment, as indicated by bioluminescence imaging and survival analysis. Immunoblot analysis revealed that resistant tumors showed greatly reduced or a complete absence of Rb protein expression. RB sequence analysis of DNA from resistant tumors failed to reveal any sequence alterations, and there was no indication of altered cytosine methylation in RB regulatory sequences. In contrast, chromatin immunoprecipitation revealed 11x (U87) and 7x (G55) reductions in RB promoter sequence association with histone H3K4 trimethyl (H3K4me3) antibody, indicating suppression of RB expression, in GBM subjected to sustained cdk4/6 inhibition, through a histone modification associated with gene silencing.
Tumor Development in Susceptible Strain A and Resistant Strain L Lung Transplants in LA F&lt;sub&gt;1&lt;/sub&gt; Hosts
Authors: W. E. Heston, Thelma B. Dunn
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Tumor Development in Susceptible Strain A and Resistant Strain L Lung Transplants in LA F1 Hosts Get access W. E. Heston, W. E. Heston geneticist Search for other works by this author on: Oxford Academic PubMed Google Scholar Thelma B. Dunn Thelma B. Dunn pathologist National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 5, April 1951, Pages 1057–1071, https://doi.org/10.1093/jnci/11.5.1057 Published: 01 April 1951 Article history Received: 13 February 1951 Published: 01 April 1951
AB0461 Efficacy of Abatacept Intravenous. Study of 45 Patients
Authors: C. Bejerano, S. Pertega, J.A. Pinto-Tasende, N. Oreiro, E. Alonso, M.T. Silva-Diaz, J. Gromaz, A. Soilán, R. Rey, E. Gismero, F.J. De Toro, F.J. Blanco, J.C. Fernández-Lόpez
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To assess the probability of withdrawal Abatacept intravenous (i.v) due to lack of efficacy and identify variables related to the survival to treatment. <h3>Methods</h3> A Retrospective, observational, open and non controlated study of clinical records of 45 patients in a third level Hospital in Northwest Spain who have been treated with Abatacept i.v in the last ten years. Statistical analysis: A descriptive analysis was performed. Compliance probability was estimated by means of Kaplan-Meier survival curves, and compared with the log-rank test. <h3>Results</h3> We studied 45 patients with a mean age at the beginning of 48,8±16,7 years and time of evolution of the disease 12.0±7,9 years. 80% were women (36 patients). 75,6% (34 patients) were Rheumatoid Arthritis, 13,3% (6) Juvenile Idiopathic Arthritis and 11.1% (5) Psoriatic Arthritis. Rheumatoid Factor (RF) was positive in 52% (28) and in 62.2% (28) the disease was erosive. Thirty five patients had combination therapy with conventional DMARDs: Azathioprine in 2 cases, 8 patients with Leflunomide and Methotrexate in 25 cases. 21 patients (46,7%) had glucocorticoids. Initially, 20,0% of cases were biologic naive, 37,8% were failure of one biologic DMARD and failure of two or more in 41,2%. Eighteen patients (40%) withdrawal Abatacept because lack of efficacy in nine patients and nine had an adverse event. Probability to continue the treatment without lack of efficacy at two years was 84,0%, at 5 years 70,9% and it is kept ten years after treatment. Probability of withdrawal Abatacept was minor in patients with positive RF (p=0,042), erosive disease (p=0,068), biologic naive (p=0,052) or patients who have received less than two biologic DMARDs (p=0,007). <h3>Conclusions</h3> The most of patients who had initiated Abatacept intravenous have continued the treatment ten years after. Probability of withdrawal due to lack of efficacy was minor in patients with positive RF, erosive disease or patients who have received less than two biologic DMARDs. <h3>Disclosure of Interest</h3> None declared
AB1033 Evidence for Autonomic Dysfunction in Familial Mediterranean Fever (FMF): Results from a Prospective Controlled Study Including the Compass-31 Questionnaire
Authors: M. Witt, K. Valda, P. Moog, O. Eren, H. Schulze-Koops, M. Grunke
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Familial mediterranean fever (FMF) is the most prevalent hereditary autoinflammatory disorder. While disease features such as fever, polyserositis and systemic amyloidosis are well recognized, little is known about the involvement of the autonomous nervous system. However, autonomic dysfunction has been identified as a major problem in autoimmune diseases such as systemic lupus erythematosus and diabetes mellitus (1). Resulting morbidities include orthostatic and gastrointestinal dysregulation and reduced heart rate variability. <h3>Objectives</h3> To prospectively investigate whether signs and symptoms of autonomic dysfunction are more prevalent in FMF patients than in age and gender matched healthy controls. <h3>Methods</h3> Patients fulfilling the classification criteria for FMF were included in the study. Data on genotype, disease activity, disease manifestations, current treatment and presence/absence of amyloidosis was gathered. Patients and healthy controls were evaluated using the COMPASS-31 questionnaire, a well-validated and feasible self-assessment instrument for the evaluation of autonomic functions and symptoms (2). Additional tests included assessment of blood pressure responses to sympathic and parasympathic stimuli, heart rate variability analysis and skin conductance measurement. <h3>Results</h3> Sofar, 18 FMF patients and 15 healthy controls were enrolled into this ongoing study. Mean age and gender distribution did not differ significantly in both groups. Compared to healthy controls, FMF patients had a significantly higher mean COMPASS-31 score (20.7±6.8 vs. 7.1±5.3, p&lt;0.05). This difference remained significant after the GI domain of the COMPASS-31 questionnaire was excluded from analysis (15.2±5.5 vs. 6.2±4.3, p&lt;0.05). Concerning the COMPASS-31 subdomains, mean scores in the vasomotor, secretomotor and GI domain were significantly higher in the FMF group than in the control group (p&lt;0.05 each), while there were no differences between patients and controls in the orthostatic, bladder and pupillomotor domain. Preliminary results of the biometric tests confirm the COMPASS-31 findings. <h3>Conclusions</h3> The presented data implies autonomic dysfunction in patients with FMF. Thorough assessment of FMF patients for the presence of ANS pathology seems to be warranted. Research involving biometric tests involving the assessment of blood pressure responses to sympathic and parasympathic stimuli, heart rate variability analysis and skin conductance measurement are now in progress to further clarify these results. <h3>References</h3> Stojanovich L et al.: Autonomic dysfunction in autoimmune rheumatic disease. Autoimmun Rev 2009; 8: 569-72. Sletten DM et al.: COMPASS-31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 2012;87:1196-201. <h3>Disclosure of Interest</h3> None declared
European Perspectives
Authors: Pim de Feyter
Journal: Circulation (2007)

is a professor of noninvasive cardiol- ogy; about 8 years ago, a joint chair in cardiology and radiology at Erasmus Medical Center was created for him.At that time, the development of noninvasive imaging techniques in cardiology needed more encouragement and support."We just invented this post," he says."As far as I know, there is no other such chair in the Netherlands.Maybe more will come in the future."Although he acknowledges that in some institutions such a dual role might be unsettling and cause friction between clinicians in the 2 departments, his personal experience has been only positive.He says, "We find it a very agreeable position.Cardiologists and radiologists share all the publications.It has promoted better communications.We feel everyone should work together in this way."The close working relationship of the cardiology and radiology departments at Erasmus, facilitated by the joint chair, has improved the interpretation of the images produced, and Dr de Feyter believes this ultimately has benefited patients.
Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses
Authors: Danuta M Skowronski, Suzana Sabaiduc, Catharine Chambers, Alireza Eshaghi, Jonathan B Gubbay, Mel Krajden, Steven J Drews, Christine Martineau, Gaston De Serres, James A Dickinson, Anne-Luise Winter, Nathalie Bastien, Yan Li
Journal: Eurosurveillance (2016)

As elsewhere, few (< 15%) sentinel influenza A(H3N2) clade 3C.2a viruses that dominated in Canada during the 2014/15 season could be antigenically characterised by haemagglutination inhibition (HI) assay. Clade 3C.2a viruses that could be HI-characterised had acquired genetic mutations during in vitro cell culture isolation that modified the potential glycosylation motif found in original patient specimens and the consensus sequence of circulating viruses at amino acid positions 158-160 of the haemagglutinin protein. Caution is warranted in extrapolating antigenic relatedness based on limited HI findings for clade 3C.2a viruses that continue to circulate globally.
AB0785 Sleep Disturbances Features in Axial Spondyloarthritis: A Case-Control Study
Authors: R. Dhahri, I. Mahmoud, O. Saidane, I. Chrif, H. Sahli, R. Tekaya, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Sleep disturbances are reported by more than 70% of patients suffering from painful disorders, including: rheumatoid arthritis (RA), osteoarthritis (OA), systemic lupus erythematosus (SLE), fibromyalgia and Sjögren9s syndrome. There is, however, a very limited research conducted on the frequency of sleep disturbances in patients with Axial Spondylarthritis (AS). <h3>Objectives</h3> The objective of this study was, to determine the prevalence of sleep disturbances among AS patients. <h3>Methods</h3> A cross sectional case-control study was conducted between August 2012 and August 2013 in the department of Rheumatology of Charles Nicolle Hospital. Only patients with Axial Spondyloarthritis according to the 2009 Eular criteria were included. Age- and sex-matched healthy controls were included in this case-control study. Sleep during the month preceding the evaluation was examined by MOS-SS. The association among sleep, pain, disease activity, functional status, were assessed. <h3>Results</h3> One hundred patients with AS and 100 control group patients age and sex matched participated in this study. Patients were divided into 71 men and 29 women. Their average age is 41.72 years [16-74]. Evaluation of sleep disorders by the MOS-SS scale highlighted a sleep disturbance in 39.9% [0-100]. Daytime sleepiness was at 39% [0 to 93.33]. The respiratory impairments: snoring was present in 55% of patients with an average value of 26.2% [0-100], shortness of breath/headache upon awakening were present in 53% of patients with a mean value of 31.8% [0-100]. The average hours of sleep per night for the past four weeks was of 6.67 hours [2 -13]. Comparing to controls significant difference was noted only with snoring (p=0.028). But, considering subgroups with active (BASDAI&gt;40), tired (EVA fatigue&gt;50) or with significant functional impairment (BASFI&gt;40), more remarkable differences appears. <h3>Conclusions</h3> Although there are more sleep disorder in AS patients. This difference was significant only in subgroups with active disease or important fatigue or patients with high functional impairment. <h3>Disclosure of Interest</h3> None declared
A Disposable Microfluidic Device for Controlled Drug Release from Thermal-Sensitive Liposomes by High Intensity Focused Ultrasound
Authors: Long Meng, Zhiting Deng, Lili Niu, Fei Li, Fei Yan, Junru Wu, Feiyan Cai, Hairong Zheng
Journal: Theranostics (2015)

The drug release triggered thermally by high intensity focused ultrasound (HIFU) has been considered a promising drug delivery strategy due to its localized energy and non-invasive characters. However, the mechanism underlying the HIFU-mediated drug delivery remains unclear due to its complexity at the cellular level. In this paper, micro-HIFU (MHIFU) generated by a microfluidic device is introduced which is able to control the drug release from temperature-sensitive liposomes (TSL) and evaluate the thermal and mechanical effects of ultrasound on the cellular drug uptake and apoptosis. By simply adjusting the input electrical signal to the device, the temperature of sample can be maintained at 37 °C, 42 °C and 50 °C with the deviation of ± 0.3 °C as desired. The flow cytometry results show that the drug delivery under MHIFU sonication leads to a significant increase in apoptosis compared to the drug release by incubation alone at elevated temperature of 42 °C. Furthermore, increased squamous and protruding structures on the surface membrane of cells were detected by atomic force microscopy (AFM) after MHIFU irradiation of TSL. We demonstrate that compared to the routine HIFU treatment, MHIFU enables monitoring of in situ interactions between the ultrasound and cell in real time. Furthermore, it can quantitatively analyze and characterize the alterations of the cell membrane as a function of the treatment time.
Infantile Cirrhosis of Liver.
Authors: V B Green-Armytage
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal